Q-omics provides the consensus-scored CACNA1H profile across patient tissues and cancer cell-line models. CACNA1H expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CACNA1H is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, CACNA1H RNA expression shows 15,922 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where CACNA1H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1H survival associations across molecular data types. CACNA1H RNA expression shows survival associations in the most cancer types (25), followed by mutation status (14) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1H RNA expression–survival associations across cancer types. High CACNA1H expression shows unfavorable associations in KIRP, LUAD, UVM and LUSC, but favorable associations in PAAD and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CACNA1H RNA expression.
This table summarizes CACNA1H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1H shows lower tumor expression in THCA, BLCA, UCEC, KIRC and KICH and higher tumor expression in HNSC. The THCA box plot shows higher CACNA1H RNA expression in normal versus tumor tissue (log2 FC = −1.815, t-test p < 0.001).
This table shows molecular features associated with CACNA1H in patient tissues and cancer cell lines. In patient samples, CACNA1H shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA1H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
